Drug intelligence / Profile preview

AOC 1072

Development stage: Preclinical
Lead developer: Avidity Biosciences
Modality: Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

AOC 1072 is an early-stage Antibody Oligonucleotide Conjugate (AOC) program developed by Avidity Biosciences, now part of SpinCo (Bryce Therapeutics, Inc.) following its spin-off from Avidity's acquisition by Novartis. This drug candidate is designed for targeted RNA delivery and is focused on treating rare genetic cardiomyopathies. It is also associated with collaboration agreements with Bristol Myers Squibb and Eli Lilly.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on AOC 1072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AOC 1072.

Explore the full profile